Which of the following is the goal of monitoring peak and trough levels during antibacterial therapy?

A. Permanent, inheritable changes to DNA:

Mutations are alterations or changes in the DNA sequence of an organism's genome. These changes can be permanent and heritable, meaning they are passed on to offspring during reproduction. Mutations can occur spontaneously or be induced by various factors such as environmental agents, radiation, or errors in DNA replication or repair mechanisms. These changes can lead to variations in traits among individuals within a population and are essential for the process of evolution.

B. An organism that is capable of causing disease:

This definition refers to the term "pathogen." Pathogens are organisms, such as bacteria, viruses, fungi, or parasites, that are capable of causing disease in their hosts. Pathogens can infect humans, animals, plants, or other organisms and can lead to a wide range of diseases, from mild infections to life-threatening illnesses.

C. The severity of a disease that an organism is able to cause:

This definition refers to the term "virulence." Virulence is a measure of the severity or harmfulness of a pathogen, indicating its ability to cause disease in a host organism. Highly virulent pathogens are more likely to cause severe illness or death, while less virulent pathogens may cause milder symptoms or asymptomatic infections. Virulence factors, such as toxins, adhesion molecules, or evasion mechanisms, contribute to the pathogen's ability to cause disease.

D. A substance that can inhibit the growth of bacteria:

This definition refers to the term "antibiotic." Antibiotics are chemical substances produced by microorganisms, fungi, or synthesized in the laboratory that can inhibit the growth of or kill bacteria. Antibiotics are commonly used to treat bacterial infections and work by targeting specific bacterial structures or metabolic processes, thereby disrupting bacterial growth and survival. However, antibiotics are not mutations; instead, they are therapeutic agents used to combat bacterial infections.

A. Kanamycin (Kantrex):

Kanamycin is an aminoglycoside antibiotic, but it is not commonly used as a first-line treatment for MRSA infections. Aminoglycosides are not typically preferred for treating MRSA because they are not as effective against these resistant bacteria compared to other agents like vancomycin.

B. Vancomycin:

Vancomycin is a glycopeptide antibiotic and is considered the drug of choice for the treatment of MRSA infections, including serious bloodstream infections, pneumonia, and skin and soft tissue infections. It works by inhibiting cell wall synthesis in bacteria, including MRSA.

C. Streptomycin:

Streptomycin is another aminoglycoside antibiotic, similar to kanamycin. Like kanamycin, streptomycin is not typically used as a first-line treatment for MRSA infections because it is less effective against resistant strains compared to other agents like vancomycin.

D. Penicillin:

Penicillin and other beta-lactam antibiotics are ineffective against MRSA because MRSA is resistant to these antibiotics, including methicillin. Therefore, penicillin would not be an appropriate choice for treating MRSA infections.